Copertina

Validating methods used to identify non‐adherence adverse drug events in Canadian administrative health data

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Maeve E. Wickham, Kimberlyn M. McGrail, Michael R. Law, Amber Cragg, Corinne M. Hohl
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	British Journal of Clinical Pharmacology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Validating use of diagnostic codes in Canadian administrative data for identification of adverse drug events
di: Maeve E. Wickham, et al.
Pubblicazione: (2024)

Re‐Exposure to Culprit Medication Following Adverse Drug Event Diagnosis in Canadian Emergency Department Patients: A Cohort Study
di: Maeve E. Wickham, et al.
Pubblicazione: (2024)

EudraVigilance insights: Suspected adverse drug reactions in infants through breastfeeding
di: Ida M. Heerfordt, et al.
Pubblicazione: (2025)

Evaluating a virtual paediatric adverse drug reaction clinic
di: Emily Hauck, et al.
Pubblicazione: (2026)

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach
di: Judith Berres, et al.
Pubblicazione: (2026)

The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United Kingdom
di: Simrit Dhillon, et al.
Pubblicazione: (2026)

Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT‐ECO study
di: Marie‐Laure Laroche, et al.
Pubblicazione: (2024)

Contribution of Addictovigilance data to assess adverse‐events linked to psychoactive substances in children and adolescents
di: Hélène Peyrière, et al.
Pubblicazione: (2025)

Development of method using language processing techniques for extracting information on drug–health food product interactions
di: Mari Yoshizaki, et al.
Pubblicazione: (2024)

Practice, knowledge and attitude of physicians and pharmacists towards the spontaneous reporting system of adverse drug reactions in Switzerland
di: Fiona A. Strobel, et al.
Pubblicazione: (2026)

Empowering citizens to spontaneously report suspected adverse drug reaction: Systematic literature review of interventions and their impact
di: Margarida Perdigão, et al.
Pubblicazione: (2026)

Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database
di: Yuko Kanbayashi, et al.
Pubblicazione: (2024)

A study on adverse events of botulinum toxin type A in real‐world applications: A FAERS database analysis
di: Weizhen He, et al.
Pubblicazione: (2025)

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System
di: Guanghan Sun, et al.
Pubblicazione: (2025)

Medication adherence to inflammatory bowel disease medications in Aotearoa New Zealand and correlation with health outcomes: A nationwide database analysis
di: Obreniokibo Ibifubara Amiesimaka, et al.
Pubblicazione: (2024)

Pan‐European survey on medication adherence management by healthcare professionals
di: Maria Kamusheva, et al.
Pubblicazione: (2024)

TFV‐DP adherence interpretations from TDF using an updated 50% methanol and 50% water extraction method for DBS
Pubblicazione: (2024)

Medication adherence—Everybody's problem but nobody's responsibility?
di: Amy Hai Yan Chan, et al.
Pubblicazione: (2024)

Comprehensive analysis of adverse event profile changes with pertuzumab addition to trastuzumab‐based breast cancer therapy: Disproportionality analysis using VigiBase
di: Tatsuaki Takeda, et al.
Pubblicazione: (2025)

Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment
di: Debbie S. Deben, et al.
Pubblicazione: (2024)

Overcoming barriers to adherence through innovative injectable medications: A systematic review of therapeutic options for cardiovascular disease, reported adherence, and perspectives on their use
di: Beata Bajorek, et al.
Pubblicazione: (2025)

Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption
di: Sarah Alrubia, et al.
Pubblicazione: (2025)

Pharmacology and relevant drug interactions of metamizole
di: David J. Brinkman, et al.
Pubblicazione: (2025)

Medication adherence and hospitalizations in older patients with coronary heart disease in Vietnam
di: Tan Van Nguyen, et al.
Pubblicazione: (2025)

Medication adherence for people with acquired communication disorders: A systematic review
di: Shauna Bell, et al.
Pubblicazione: (2024)

Effects of age, sex, daily dose, comorbidity and co‐medication on venlafaxine‐associated cardiovascular adverse events: A pharmacovigilance analysis of the FDA Adverse Event Reporting System database
di: Zhanzhang Wang, et al.
Pubblicazione: (2024)

Pharmacokinetic drug–drug interactions with flucloxacillin and other isoxazolyl penicillins: A systematic literature review and practical guide
di: Julia M. Wortman, et al.
Pubblicazione: (2026)

Turkish translation and cultural adaptation of the Ascertaining Barriers to Compliance taxonomy for medication adherence
di: Cansu Goncuoglu, et al.
Pubblicazione: (2025)

Risk of bias tools for medication adherence research: RoBIAS and RoBOAS
di: Klarissa A. Sinnappah, et al.
Pubblicazione: (2025)

Longitudinal non‐cancer pain management patterns and risk of adverse outcomes in older adults: Insights from group‐based multi‐trajectory modelling
di: I‐Tzu Chen, et al.
Pubblicazione: (2025)

Hair analysis of formoterol as a novel tool to assess long‐term inhalation medication adherence: Data from the TRICOLON trial
di: Liz J. A. Cuperus, et al.
Pubblicazione: (2026)

Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model
di: Sara Merdita, et al.
Pubblicazione: (2024)

A systematic review of medication adherence and mortality in chronic disease: Implications for clinical guidelines and policy
di: Jessica Hamuy Blanco, et al.
Pubblicazione: (2025)

Clinician's attitudes & perspective on chemical adherence testing in hypertension (CATCH): A qualitative interview study
di: Roshan Shahab, et al.
Pubblicazione: (2026)

Validity of the Medication Safety Self‐Assessment for Long‐Term Care tool in Australian long‐term care: a RAND appropriateness method study
di: Ramesh Sharma Poudel, et al.
Pubblicazione: (2025)

Experience of a nirmatrelvir/ritonavir drug–drug interaction expert advice service
Pubblicazione: (2024)

A case report highlighting drug–drug interactions between 3 life‐saving treatments: Feminizing hormones, antiretrovirals and antituberculosis drugs
di: Tara Suchak, et al.
Pubblicazione: (2024)

Lack of clinically significant drug–drug interactions between the third‐generation integrase strand transfer inhibitor VH4524184 (VH‐184) and combined oral contraceptives
di: E. Doyle, et al.
Pubblicazione: (2025)

Medication adherence during the run‐in phase of clinical trials: A systematic review of methodological and reporting rigour
di: Non Davies, et al.
Pubblicazione: (2025)

Assessing the anticholinergic cognitive burden classification of putative anticholinergic drugs using drug properties
di: Geofrey Oteng Phutietsile, et al.
Pubblicazione: (2024)